Brief: Santhera And Reveragen Announce New 2.5-Year Treatment Data With Vamorolone

Santhera Pharmaceuticals Holding AG

28/04/2021 06:04

April 28 (Reuters) - Santhera Pharmaceuticals Holding AG
 SANN.S :
    * SANTHERA AND REVERAGEN ANNOUNCE NEW 2.5-YEAR TREATMENT
DATA WITH
VAMOROLONE IN DUCHENNE MUSCULAR DYSTROPHY
    * LONG-TERM TREATMENT WITH VAMOROLONE RESULTED IN
SIGNIFICANTLY
FEWER CORTICOSTEROID-ASSOCIATED ADVERSE EVENTS THAN REPORTED IN
OTHER CLINICAL TRIALS WITH OTHER STEROIDS.

Source text for Eikon:  ID:nGNE7yVRXv 
Further company coverage:  SANN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))